University of Lille Nord de France

DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO

Retrieved on: 
Tuesday, September 27, 2022

The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.

Key Points: 
  • The company simultaneously announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology.
  • Mr. Grmusa, Dr. Quva and Dr. Francisco-Anderson join experienced industry leader John McCabe who serves as Chief Financial Officer and Chief Operating Officer.
  • I am thrilled to join DEM Bio and to work alongside this world-class team of leaders in the emerging and highly promising field of innate immune system checkpoint inhibitors, said Mr. Grmusa.
  • Mr. Grmusa brings 20 years of industry experience in business development, pharmaceutical portfolio management, R&D finance and financial planning and analysis.

Bruker Introduces Enabling New Scientific Capabilities for Cell Biology and Pathobiology Research with High-Field NMR Innovations

Retrieved on: 
Monday, August 22, 2022

The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.

Key Points: 
  • The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.
  • It allows researchers to obtain essential information in crowded IDP spectral regions for the unambiguous assignment of IDP backbone resonances.
  • I am very excited to see which previously inaccessible but important scientific and pathobiology questions this innovative NMR technology can address.
  • Dr. Guido Pintacuda, CNRS Research Director and Director of the Lyon High-field NMR Center explained: The new Bruker 160 kHz MAS HCN probe will push structural, cellular and disease biology research into the next phase of the solid-state NMR scientific evolution.

ImaBiotech Supports the Institut Pasteur de Lille and Apteeus for the Development of Covid-19 Therapy

Retrieved on: 
Monday, June 28, 2021

The high molecular specificity of Mass Spectrometry Imaging, combined with rapid method development highlighted the added value of this technique over other technologies.

Key Points: 
  • The high molecular specificity of Mass Spectrometry Imaging, combined with rapid method development highlighted the added value of this technique over other technologies.
  • The next step is to demonstrate the medical value through a clinical trial, sponsored by the Institut Pasteur de Lille and led by Professor Benoit Deprez.
  • Institut Pasteur de Lille is a private, non-profit foundation with recognized public utility status since 1898.
  • As an international center for biomedical research, Institut Pasteur de Lille focuses on Longevity fundamental research, education and public health to ensure we live better for longer.